A short peptide reverses the aggressive phenotype of prostate cancer cells

Eur J Pharmacol. 2018 Nov 5:838:129-137. doi: 10.1016/j.ejphar.2018.09.013. Epub 2018 Sep 6.

Abstract

Previous studies have demonstrated that fibroblast growth factor 8b (FGF8b) is up-regulated in a large proportion of prostate cancer patients, and plays a key role in the aggressive progress of prostate cancer. Herein, we investigated the effects of a short peptide derived from the gN helix domain of FGF8b on the metastatic behaviors of prostate cancer cells. The results demonstrated that the synthetic peptide might reverse the effects of FGF8b on cell proliferation, migration and invasion by suppressing the activation of MAPK and Akt signaling cascades, and reducing the expressions of the metastasis-related proteins, resulting in suppression of the aggressive phenotype of the prostate cancer cells. Collectively, these results underline the therapeutic potential of the FGF8b mimic peptide in advanced prostate cancer.

Keywords: Aggressive phenotype; Fibroblast growth factor 8; Prostate cancer.

MeSH terms

  • Cell Line, Tumor
  • Cell Movement / drug effects
  • Cell Proliferation / drug effects
  • Drug Screening Assays, Antitumor
  • Fibroblast Growth Factor 8 / antagonists & inhibitors*
  • Fibroblast Growth Factor 8 / chemistry
  • Fibroblast Growth Factor 8 / metabolism
  • Humans
  • MAP Kinase Signaling System / drug effects
  • Male
  • Neoplasm Invasiveness / pathology
  • Neoplasm Invasiveness / prevention & control
  • Peptides / chemistry
  • Peptides / pharmacology*
  • Peptides / therapeutic use
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / pathology
  • Protein Domains
  • Protein Isoforms / antagonists & inhibitors
  • Protein Isoforms / chemistry
  • Protein Isoforms / metabolism

Substances

  • FGF8 protein, human
  • Peptides
  • Protein Isoforms
  • Fibroblast Growth Factor 8